Skip to main content

Table 1 Model parameters and references

From: The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments

Parameter

Symbol

Value

References

Duration of injecting career

1/μ1

14 years

Fazito et al. global average [26]

Mortality rate

μ2

0.0083 per year

Stoové et al. [27]

Exit rate

μ

μ1 + μ2 per year

 

Proportion at high risk, defined as the proportion of PWID experiencing unstable housing [16]

Vary η to calibrate

0.17

O’Keefe et al. [28]

Duration at high risk

12/κ

13 months

O’Keefe et al. [28]

Recruitment to high risk

η

Calibrated to proportion at high risk

 

Infection risk factor of high-risk PWID compared to low-risk PWID

Γ

3.6

Turner et al. [29], Allen et al. [30], Aitken et al. [31]

Infection rate

Ï€

Calibrated to initial prevalence

 

Proportion of infected who spontaneously clear

δ

0.26

Micallef et al. [24]

Proportion treated who are cured (interferon-free DAAs, all genotypes)

α

0.9

Lawitz et al. [10], Gane et al. [11], Poordad et al. [12]

Treatment duration (interferon-free DAAs, all genotypes)

52/ω

12 weeks

Lawitz et al. [10], Gane et al. [11], Poordad et al. [12], Chen et al. [32]

Vaccine efficacy

ε

30 %, 60 %, 90 %

Assumed

Vaccine duration of protection

 

Greater than the length of injecting career

Assumed

  1. DAA direct-acting antiviral, PWID people who inject drugs